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The family of tripartite-motif (TRIM) proteins are involved
in diverse cellular processes, but are often characterized
by critical protein–protein interactions necessary for their
function. TRIM16 is induced in different cancer types,
when the cancer cell is forced to proceed down a differentia-
tion pathway. We have identiﬁed TRIM16 as a DNA-binding
protein with histone acetylase activity, which is required
for the retinoic acid receptor b2 transcriptional response
in retinoid-treated cancer cells. In this study, we show
that overexpressed TRIM16 reduced neuroblastoma cell
growth, enhanced retinoid-induced differentiation and reduced
tumourigenicity in vivo. TRIM16 was only expressed in the
differentiated ganglion cell component of primary human
neuroblastoma tumour tissues. TRIM16 bound directly to
cytoplasmic vimentin and nuclear E2F1 in neuroblastoma
cells. TRIM16 reduced cell motility and this required down-
regulation of vimentin. Retinoid treatment and enforced
overexpression caused TRIM16 to translocate to the nucleus,
and bind to and downregulate nuclear E2F1, required for cell
replication. This study, for the ﬁrst time, demonstrates that
TRIM16 acts as a tumour suppressor, affecting neuritic
differentiation, cell migration and replication through
interactions with cytoplasmic vimentin and nuclear E2F1
in neuroblastoma cells.
Oncogene (2010) 29, 6172–6183; doi:10.1038/onc.2010.340;
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Introduction
The tripartite motif (TRIM) protein family is composed
of more than 70 highly conserved proteins, which
display three similar structural motifs: N-terminal,
RING-B box-coiled-coil domains and a variable
C-terminus. TRIM proteins have been ascribed impor-
tant roles in development, ubiquitination, retroviral
immunity and cancer, but commonly depend on
protein–protein interactions to fulﬁl their cellular
functions (Le Douarin et al., 1995; Cao et al., 1998;
Meroni et al., 2005; Vichi et al., 2005).
TRIM16, also called the oestrogen-responsive B box
protein, is a member of the RING-B box-coiled-coil/
TRIM protein family, and is constitutively expressed in
many tissues in a nascent and post-translationally
modiﬁed form (Liu et al., 1998). In contrast to most
B-box family members, TRIM16 has a predominantly
cytoplasmic localization. TRIM16 is missing the RING
ﬁnger domain, but has, in addition, a C-terminal Ret
ﬁnger, or B30.2 (SPRY), domain of unknown function.
This is shared with several other tripartite motif
proteins, such as Midline 1 (MID1/TRIM 18) and
TRIM 20, mutated in the human disorders Opitz
syndrome and Familial Mediterranean fever, respec-
tively (Trockenbacher et al., 2001; Chae et al., 2003).
In search for factors that mediate the retinoid
anticancer signal, we have shown that the TRIM16
protein binds DNA and has histone acetyltransferase
activity, which is required for the retinoid-induced
retinoic acid (RA) receptor b2 transcriptional response
and growth inhibition in retinoid-treated cancer cells
(Cheung et al., 2006; Raif et al., 2009). TRIM16 is a
ubiquitously expressed protein that is predominantly
cytoplasmic, and undergoes serine–threonine phosphor-
ylation and increased protein stability following retinoid
treatment. TRIM16 expression is also induced by
oestrogen in breast cancer cells and keratinocyte growth
factor in keratinocytes, as cells are entrained to undergo
differentiation (Liu et al., 1998; Beer et al., 2002).
TRIM16 reduced the cell viability in retinoid-sensitive
neuroblastoma cells and retinoid-resistant breast and
lung cancer cells, whereas the viability of non-cancer
cells was unaffected by TRIM16 overexpression
(Cheung et al., 2006; Raif et al., 2009). Importantly,
exogenous TRIM16 overexpression in retinoid-resistant
cancer cells induced retinoid sensitivity, making
TRIM16 an important target for future differentiation
therapy development in cancer.
Neuroblastoma is the most common solid tumour of
early childhood, originating from cells that form the
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www.nature.com/oncnormal sympathetic nervous system. The tumour cells
have embryonic features, presumably as a consequence
of an impaired capacity to respond to signals operating
during normal differentiation. RA causes ganglionic
differentiation of neuroblastoma cell lines in vitro,
characterized by the appearance of long neurites and
cell growth arrest (Thiele et al., 1985). This observation
led to successful clinical trials in children with advanced
neuroblastoma, showing that retinoid therapy signiﬁ-
cantly improved survival in these patients (Matthay
et al., 1999, 2009).
The signalling pathways and mechanisms underpin-
ning the effect of TRIM16 in retinoid-treated cancer
cells are yet to be fully delineated. Owing to the
profound effects of TRIM16 overexpression in the
presence of retinoids, we examined the hypothesis that
TRIM16 may act as a tumour suppressor in the absence
of retinoids, and, moreover, that protein–protein inter-
actions might explain its cellular effects. In this study, we
show that TRIM16 is an important regulator of neuro-
blastoma cell differentiation, migration and tumouri-
genicity, via its interaction with cytoplasmic vimentin and
nuclear E2F1 proteins in neuroblastoma cells.
Results
TRIM16 reduces neuroblastoma cell viability,
clonogenicity and tumourigenicity
We have previously shown that TRIM16 can enhance
the retinoid anti-proliferative effect on cancer cells
through transcriptional regulation of retinoic acid
receptor b2. In this study, we sought to investigate
whether TRIM16 had a tumour suppressor function in
neuroblastoma, independent of its effects on the retinoid
anticancer signal. We derived stable neuroblastoma
BE(2)-C cell lines, which overexpressed TRIM16
(Figure 1a). In an Alamar Blue assay (Figure 1b),
overexpression of TRIM16 in neuroblastoma tumour
cells decreased the cell viability in two independently
derived clones (TRIM16-4 and TRIM16-5), compared
with empty vector clones (EV-1 and EV-8) (Po0.001).
Anchorage-independent growth in soft agar was also
reduced in TRIM16-expressing clones, compared with
control clones (Po0.01) (Figures 1c and d). In a
xenograft BALB/c nude mouse model, TRIM16 over-
expression led to substantially decreased neuroblastoma
tumour growth, as compared with the empty vector
controls, 4 weeks post engraftment (Po0.01)
(Figure 1e). Together, these data indicated that TRIM16
inhibited the tumourigenic phenotype of neuroblastoma
tumour cells in the absence of excess retinoid. Further-
more, we examined the effect of knockdown of TRIM16
expression on cell growth. The efﬁciency of TRIM16
small interfering RNA (siRNA) was evaluated after 24,
48 and 72h of transfection by western blot (70%
knockdown). The cell viability of BE(2)-C was signiﬁ-
cantly increased after transfection of 20 nM siRNA
TRIM16 when compared with control siRNA
(Po0.001) (Figure 1f).
TRIM16 induces neuronal differentiation
in neuroblastoma cells
TRIM16 expression is increased by oestrogen, kerati-
nocyte growth factor and retinoic acid in breast cancer,
skin and neuroblastoma cells, respectively (Liu et al.,
1998; Beer et al., 2002; Cheung et al., 2006). In order to
investigate the mechanism of the TRIM16 tumour
suppressor function, TRIM16-expressing BE(2)-C neu-
roblastoma cell clones were examined for neuritic
differentiation in vitro in the presence of retinoid, and
compared with control clones. Overexpression of
TRIM16 led to a signiﬁcant increase in the proportion
of neurite-bearing cells after 10mM all-trans-retinoic acid
(aRA) treatment at days 4 and 6, compared with empty
vector controls (Po0.001) (Figures 2a and b).
Neuroblastoma tumour tissue is composed of primi-
tive neuroblasts, more differentiated mature ganglion
cells and interstitial neuropil. Moreover, a high degree
of ganglion cell maturation within a tumour correlates
with a better patient prognosis (Joshi, 2000). We
therefore wanted to investigate whether TRIM16 was
selectively expressed in particular cell types within the
neuroblastoma tumour tissue. Parafﬁn-embedded, for-
malin-ﬁxed human neuroblastoma tumour cross-sec-
tions were examined for the pattern of endogenous
TRIM16 expression by immunohistochemical staining
using a TRIM16-speciﬁc antibody in 21 patients from
ﬁve clinical stages (stage I, II, III, IV and IVS). The
expression of TRIM16 was stronger in the large
ganglion cells and interstitial neuropil, which comprise
the more differentiated component of the tumour, and is
largely absent in the smaller primitive neuroblasts
(Figure 2c). The proportion of TRIM16-positive cells
was signiﬁcantly higher in the differentiated region,
compared with the poorly differentiated region
(Po0.001) across all clinical stages (Figure 2d). How-
ever, there was no statistically signiﬁcant relationship
between clinical stage and TRIM16 protein expression.
We conﬁrmed the differentiated nature of the region of
the neuroblastoma tumour shown in Figure 2e, by
demonstrating co-expression of the neuronal marker,
class III b-tubulin isotype (Katsetos et al., 1991).
Furthermore, immunohistochemical staining revealed a
strong nuclear and cytoplasmic TRIM16 expression in
neonatal differentiated superior cervical ganglia cells,
coeliac ganglia cells and normal adrenal gland. In
contrast, TRIM16 expression is reduced in poorly
differentiated neuroblastoma tumour cells and is pre-
dominately in the cytoplasm of 6-week-old TH-MYCN
transgenic mouse tumours (Weiss et al., 1997).
TRIM16 binds to and modulates vimentin protein
expression in both neuroblastoma and lung cancer cells
TRIM proteins commonly bind to other proteins to
affect cellular function (Urano et al., 2002); thus, we
investigated TRIM16-binding proteins in neuroblasto-
ma cells. We examined protein lysates from BE(2)-C
cells, transiently transfected with full-length TRIM16
tagged with an MYC oligopeptide for 48h. As a
negative control, we compared lysates from cells that
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was immunoprecipitated by an anti-MYC-Tag anti-
body. Protein bands were cut directly from the gel and
micro-sequenced by the liquid chromatography-tandem
mass spectrometry (LC-MS/MS) analyses. We have
identiﬁed seven candidate TRIM16-binding partners
(vimentin, E2F1, prohibitin, TRAP-1, EBNA2 co-
activator p100, EPLIN and scaffold attachment factor
A) in this way. We then performed immunoprecipitation
and immunoblotting experiments on four of the
candidate binding partners, and conﬁrmed that vimen-
tin, E2F1 and prohibitin indeed interact with TRIM16
in BE(2)-C cells. As vimentin expression is not only a
marker associated with the invasive phenotype of cancer,
but is also required for carcinoma cell motility, and E2F1
is a transcription factor that is central for cell survival and
proliferation, vimentin (a cytoplasmic protein) and E2F1
(a nuclear protein) were chosen for further studies.
Vimentin is the predominant intermediate ﬁlament
protein in mesenchymal cells, and is implicated in
metastasis and cancer cell migration in colon and breast
cancer cell lines (McInroy et al., 2007). To determine
whether TRIM16 interacted with vimentin, co-immu-
noprecipitation (co-IP) of vimentin with Myc-TRIM16
Figure 1 TRIM16 reduces neuroblastoma cell viability, clonogenicity and tumourigenicity. (a) The cells were stained with an
antibody recognizing the Myc-tag epitope to conﬁrm the TRIM16 plasmid transfection by immunoﬂuorescence microscopy and
immunoblot examination. (b) The viable cells were measured up to day 4 by Alamar Blue assay in BE(2)-C cells stably transfected with
empty vector or with TRIM16 plasmid DNA. A statistically signiﬁcant difference (**Po0.01 and ***Po0.001) compared with the
empty vector control. (c) In the top panel, the clonogenicity of various BE(2)-C cell transfectants was determined using soft agar. In the
bottom panel, number of colonies were compared between empty vector control (EV-1) and TRIM16 plasmid transfected BE(2)-C cell.
(d) A colony-forming assay showed reduced colony size in clones overexpressing TRIM16. A statistically signiﬁcant difference
(Po0.0001) compared with empty vector control (EV-1). (e) The tumour volume of TRIM16 or empty vector transfected BE(2)-C cells
injected into nude mice for 4 weeks. Each value shown in the ﬁgure represented data from 16 mice. A statistically signiﬁcant difference
(Po0.01) compared with empty vector control (EV-1). (f) In the left panel, western blotting analysis by TRIM16-speciﬁc antibody
at 24, 48 and 72h of BE(2)-C cells without or with TRIM16 siRNA transfection. Actin was used as an internal control for loading.
In the right panel: the viable cells were measured up to 72h by Alamar Blue assay in BE(2)-C cells transfected with control siRNA or
TRIM16 speciﬁc siRNA.
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BE(2)-C neuroblastoma and SK-MES-1 lung cancer
cells. Co-IP conﬁrmed that TRIM16 and vimentin for-
med a complex in both cancer cell types (Figure 3a).
TRIM16 markedly reduced vimentin protein expression
or increased vimentin expression, as shown by TRIM16
overexpression or siRNA knockdown experiments,
respectively (Figures 3b and c). The level of vimentin
mRNA did not change in BE(2)-C and SK-MES-1 cells
with overexpression of TRIM16 (data not shown). As
previously published (Beer et al., 2002), TRIM16 was
predominantly found in the cytoplasm and to a lesser
Figure 2 TRIM16 induces neuronal differentiation in neuroblastoma cells. (a, b) Up to 6 days of 10mM all-trans-retinoic acid (aRA)
treatment or ethanol control, cell differentiation was assessed by analysing neurite outgrowth under phase contrast microscopy. Cell
images were captured and stored, and neurite outgrowth was quantiﬁed. Error bars indicate s.e. A statistically signiﬁcant difference
(**Po0.001) compared with empty vector control. (c) Immunohistochemical staining for TRIM16 expression in a primary human
neuroblastoma tumour (stage I). In the tumour tissue, endogenous TRIM16 was expressed (brown staining) higher in large mature
ganglion cells and less in the neuroblasts (small blue round cells). (d) The percentage of TRIM16-positive cells were compared between
differentiated regions and poorly differentiated regions in the tumour tissues from 21 neuroblastoma patients. (e) A formalin-ﬁxed
tissue section from the same patient of Figure 2c was subjected to immunohistochemical assessment of class III b-tubulin protein
expression (brown staining). (f) Immunohistochemical staining for expression of TRIM16 (brown staining) in MYCN mice, using an
anti-TRIM16 antibody (scale bar: 100mm).
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localization of endogenous TRIM16 and vimentin pro-
teins in neuroblastoma cells was determined by confocal
microscopy. In Figure 3d, the merged image of vimentin
and TRIM16 expression showed that the endogenous
proteins were colocalized to the cytoplasm.
Downregulated vimentin is required for TRIM16 effects
on cell motility and migration
We next tested the hypothesis that TRIM16 over-
expression may reduce cell motility via its interaction
with vimentin in neuroblastoma cells. We transiently
transfected TRIM16 plasmid DNA and empty vector
control into BE(2)-C neuroblastoma cells. To optimize
transfection conditions, we measured the effects of
increasing amounts of plasmid DNA, while maintaining
a constant volume of lipofectamine. Maximum efﬁ-
ciency was found to occur between 10 to 15mgo f
plasmid per 1 10
6 cells in T75 ﬂasks; 70% of cells were
typically TRIM16-myc positive (Figure 4a). The scratch-
Figure 3 TRIM16 binds to and modulates vimentin protein
expression in both neuroblastoma and lung cancer cells.
(a) Interaction of TRIM16 with vimentin. Lysates of BE(2)-C
and SK-MES-1 cells transfected with TRIM16 plasmids were
analysed by immunoblotting using anti-vimentin and anti-Myc-tag
antibodies (western blots: vimentin and TRIM16 proteins),
combined without (input) or with immunoprecipitation using
anti-TRIM16 antibody or anti-IgG antibody control. (b) TRIM16
overexpression downregulates exogenous vimentin. Lysates of
transfected BE(2)-C and SK-MES-1 cells were analysed by anti-
TRIM16 (top panel) or anti-vimentin (middle panel) or anti-actin
as loading control (bottom panel). (c) BE(2)-C and SK-MES-1 cells
were transfected with either control siRNA or siRNA speciﬁcally
targeting TRIM16 for 72h, followed by protein extraction and
western blot. (d) Immunocytochemical expression patterns vimen-
tin (orange/red ﬂuorescence) and TRIM16 (green ﬂuorescence) in
BE(2)-C cells colocalized in the cytoplasm (visualized as yellow
ﬂuorescence in merge panel).
Figure 4 Downregulated vimentin is required for TRIM16 effects
on cell motility. (a) Lysates of BE(2)-C cells transfected with
TRIM16 plasmids were analysed by immunoblotting and an
immunoﬂuorescence assay using anti-Myc antibody. (b) Relative
closure of BE(2)-C wounds. The average distance moved by the
empty vector control and the average (and s.e.) movement of
TRIM16 plasmid DNA transfected cells in three independent
wounds is shown relative to the percentage of original wound.
Three locations of three independent empty vector control and
TRIM16 plasmid DNA transfected wounds were photographed at
8, 24 and 48h post wound. (c) Representative phase contrast
micrographs of closure of scratch-wounded conﬂuent cultures of
empty vector or TRIM16 plasmid DNA transfected BE(2)-C cells
at time point immediately after wounding and 24 and 48h post
wounding.
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investigate cell motility (McInroy et al., 2007). The BE(2)-
C cells, which overexpressed TRIM16, remained largely
open at multiple time points, while empty vector control
cells migrated particularly rapidly in this assay, ﬁlling the
empty wound space (Figures 4b and c).
To investigate whether repression of vimentin expres-
sion by TRIM16 is required for cell motility and
proliferation in neuroblastoma cells, we transiently
transfected both TRIM16 and vimentin plasmid DNA
into BE(2)-C cells for 48h, and quantiﬁed wound
closure at 32h post-scratch. In Figure 5a, the anti-His-
tag antibody and anti-Flag-tag antibody were used to
conﬁrm exogenous TRIM16 and vimentin overexpres-
sion, respectively. Overexpression of TRIM16 caused
signiﬁcantly slower wound closure at 32h, compared
with vimentin transfectants and empty vector control
(Po0.0001) (Figure 5b). Signiﬁcantly, ectopic over-
expression of both TRIM16 and vimentin into BE(2)-C
cells blocked the inhibitory effect of TRIM16 on wound
closure (Figure 5b). In contrast, overexpressed vimentin
did not abrogate the inhibitory effect of TRIM16 on cell
proliferation (Figure 5c). To investigate the role of
TRIM16 and vimentin in neuroblastoma cell migration,
we examined the invasiveness of BE(2)-C cells in a
Transwell plate migration assay using 10% fetal calf
serum as a chemoattractant. As shown in Figure 5d,
overexpression of TRIM16 demonstrated slower cell
migration at 24h compared with the empty vector
control (P¼0.04). In contrast, overexpression of
vimentin demonstrated increased cell migration at 24h
compared with empty vector control (P¼0.04).
Signiﬁcantly, ectopic overexpression of both TRIM16
and vimentin into BE(2)-C cells restored the cell
migration index to control levels. These data indicate
that repression of vimentin expression is speciﬁcally
required for TRIM16 to exert its inhibitory effects on
cell migration.
TRIM16 translocates to the nucleus and decreases nuclear
E2F1 levels in neuroblastoma cells
Our LC–MS/MS analysis identiﬁed the nuclear tran-
scription factor and cell cycle regulatory protein, E2F1
(Johnson et al., 2006), as a potential TRIM16-binding
protein. We hypothesized that TRIM16 might also
translocate to the nucleus and directly interact with
E2F1 to affect neuroblastoma cell proliferation. To test
this hypothesis, BE(2)-C neuroblastoma cells were
transiently transfected with TRIM16 plasmid DNA;
then, 24h later, nuclear and cytoplasmic protein
fractions were subjected to co-IP with a Myc-tagged
antibody, which recognized the transfected TRIM16.
Co-IP conﬁrmed that transfected TRIM16 indeed
formed a complex with endogenous E2F1 in neuroblas-
toma cells (Figure 6a). To determine whether TRIM16
regulates E2F1 protein expression in the nucleus, BE(2)-
C cells were transiently transfected with TRIM16
plasmid DNA, or treated with 10mM aRA for 48h.
As shown in Figures 6b and c, the amount of TRIM16
protein in the nucleus was increased in cells after
both aRA treatment and TRIM16 transfection, when
compared with untreated control cells. Following
aRA treatment, TRIM16 exhibited marked nuclear
Figure 5 Downregulated vimentin is required for TRIM 16 reduction of cell motility and cell migration. (a) Lysates of BE(2)-C cells
transfected with indicated plasmids (lane 1: pcDNA3.1 and pCMV-6 empty vectors; lane 2: vimentin; lane 3: TRIM16; and lane 4:
TRIM16/vimentin) were analysed by immunoblotting using anti-His and anti-Flag antibodies. (b) The average distance migrated by
the two empty vector controls (lane 1), TRIM16 (lane 2), vimentin (lane 3) and TRIM16/vimentin (lane 4) plasmid DNA-transfected
cells in three independent wounds is shown relative to the percentage of original wound. (c) BE(2) cells were transfected with different
plasmid DNA for 72h, followed by incubation with 5-bromo-2-deoxyuridine (BrdU) for the last 6h. BrdU incorporation was
measured as OD units of absorbance. (d) Invasion assay of BE(2)-C cells through collagen-coated cell culture inserts. The percentage of
the migrated cells divided by the total number of cells in the wells from three independent experiments is shown.
TRIM16 acts as a tumour suppressor in neuroblastoma cells
GM Marshall et al
6177
Oncogenetranslocation at 48h, coinciding with a reduction in
nuclear E2F1 (Figure 6b). In neuroblastoma cells
transfected with TRIM16, there was an even greater
increase in overall cellular TRIM16, with some of the
excess TRIM16 moving to the nucleus. Interestingly, the
transfected nuclear TRIM16 levels fell quickly to basal
levels by 48h post-transfection. Higher nuclear TRIM16
levels post-transfection again correlated with a twofold
reduction in nuclear E2F1 levels at 48h (Figure 6c). The
level of E2F1 mRNA did not change in BE(2)-C cells
with overexpression of TRIM16 (data not shown).
To determine whether the higher basal E2F-1 levels in
neuroblastoma cells affected cell proliferation, we
transiently transfected siRNAs targeting E2F1 or
control siRNA into BE(2)-C cells, in the presence or
absence of 10mM aRA for 72h. E2F1 siRNAs knocked
down E2F1 expression and reduced cell proliferation by
more than 90% in both aRA-treated and untreated cells
Figure 6 TRIM16 translocates to the nucleus and decreases E2F1 levels in BE(2)-C cells. (a) The nuclear protein extract from BE(2)-
C cells transfected with TRIM16 plasmids was incubated with either a mouse IgG (right lane) or an anti-Myc antibody (middle lane).
The puriﬁed IP complex was analysed by western blot using antibodies for TRIM16 and E2F1 proteins. (b, c) Immunoblotting analysis
of expression of TRIM16 and E2F1 in BE(2)-C cells. Cytoplasmic (CP) and nuclear (NP) proteins of cells treated with 10mM all-trans-
retinoic acid (aRA) for 24 and 48h (Figure 6b) or transfected with TRIM16 plasmid DNA for 24 and 48h (Figure 6c) were analysed by
immunoblotting using anti-TRIM16 and anti-E2F1 antibodies. Anti-actin antibody is used as loading control, anti-histone H3 is used
as control for nuclear protein and anti-GAPDH antibody is used as cytoplasmic protein control. (d, e) BE(2)-C cells were transfected
with control siRNA or siRNA speciﬁcally targeting E2F1 for 72h, followed by real-time PCR and 5-bromo-2-deoxyuridine (BrdU) cell
proliferation assay. A statistically signiﬁcant difference (***Po0.001) compared with control siRNA. (f) BE(2) cells were transfected
with different plasmid DNA for 72h, followed by incubation with BrdU for the last 6h. BrdU incorporation was measured as OD
units of absorbance.
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of both TRIM16 and E2F1 into BE(2)-C cells partially
blocked the inhibitory effect of TRIM16 on cell
proliferation, compared with TRIM16-transfected cells
alone (P¼0.002) (Figure 5f). These results suggested
that TRIM16’s effects on neuroblastoma cell growth
required nuclear translocation of TRIM16 protein,
binding to E2F1 protein with a consequent reduction
in nuclear E2F1 levels.
To map the interaction domains of TRIM16 and
E2F1, GFP-tagged TRIM16 domains and Flag-tagged
E2F1 were used in co-IP experiments. The coiled-coil
domain of TRIM16 is required for TRIM16 and E2F1
interaction, but not the two B-Box domains or the B30.2
domain (Figure 7a). Next, we used the cycloheximide-
blocking method to determine whether TRIM16 expres-
sion induces proteolysis of E2F1. These experiments
were performed by transfecting BE(2)-C cells with
plasmids expressing E2F1 or TRIM16 full-length, or
TRIM16 deletion mutants. As expected, E2F1 decayed
at faster rates in the presence of full-length TRIM16
than in its absence (Figure 7b). The half-life of E2F1
was reduced from greater than 4h to less than 2h. We
observed that the half-life of E2F1 was also reduced in
the presence of TRIM16 mutant 1 and mutant 3, but not
TRIM16 mutant 2, which suggested that the effect of
TRIM16 on the degradation of E2F1 was mediated by
the coiled-coil domain of TRIM16.
Discussion
Arrested tissue differentiation is a key causal feature of
many human cancer types. Differentiation therapy for
cancer offers the signiﬁcant advantages of tissue
speciﬁcity, high efﬁcacy and low toxicity. A better
understanding of the molecular mediators of the
differentiation response in cancer cells will lead to an
improved therapeutic index compared with general
cytotoxic drugs. TRIM16 has an important role in the
differentiation response of neuroblastoma cells. As a
general rule, TRIM proteins appear to function as a
component of large multi-protein complexes (Short
et al., 2006). Our previous study had shown that
TRIM16 is a nuclear transcription factor with essential
effects on the retinoid anticancer signal through
transcriptional regulation of retinoic acid receptor-b2.
In this study we show that TRIM16 demonstrates the
properties of a tumour-suppressor protein. Surprisingly,
Figure 7 Identiﬁcation of the interaction domains of TRIM16 and E2F1. (a) Interaction of individual TRIM16 domains with E2F1:
Flag-tagged E2F1 and individual domains of TRIM16 were coexpressed in BE(2)-C cells. Flag- and GFP-tagged immunoprecipitates
(IPs) were analysed for the presence of Flag- and GFP-tagged constructs (co-IPs) by western blots. Transfection of E2F1 together with
the empty vector was used as a control. Non-speciﬁc bands are labelled by asterisks. (b) TRIM16 downregulates the protein E2F1 level
by reducing the protein’s half-life: BE(2)-C cells were transfected either with E2F1 or TRIM16, as well as E2F1 and TRIM16 mutants
where indicated. After 16h the transfected cells were trypsinized, pooled and then replated. After 24h, cycloheximide was added at a
ﬁnal concentration of 25mg/ml to the media. At the speciﬁed time points the cells were harvested and the protein extracted for analysis
by western blots. The western blots were probed with polyclonal rabbit anti-E2F1 or anti-actin antibodies. Actin was used a protein
loading control.
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and nucleus, which lead to reduced levels of cytoplasmic
vimentin and nuclear E2F1, and have consequent effects
on cell migration and growth, respectively.
Our data demonstrated that in neuroblasts, TRIM16
promoted neuritic differentiation. Neurogenesis involves
both proliferation and differentiation. Human neuro-
blastoma cells show enhanced numbers of neurites and
longer processes in response to aRA. The mechanism
whereby retinoids regulate neurite outgrowth includes,
but is not limited to, the regulation of the transcription
of neurotrophin receptors (Encinas et al., 2000). More
recent evidence supports a role for aRA in regulating
components of other signalling pathways or candidate
neurite-regulating factors. Some of these effects, such as
that on neuron navigator 2, may be direct, whereas
others may be secondary to other aRA-induced changes
in the cell (Muley et al., 2008). In this study, our data
have demonstrated that overexpression of TRIM16 led
to a signiﬁcant increase in the percentage of neurite-
bearing cells during aRA treatment, and suggested that
TRIM16 is a novel candidate neurite-regulating factor
and may have an important role in retinoid-induced
neuronal differentiation.
TRIM proteins form large protein complexes through
self-interaction, which is most likely mediated via the B
box and coiled-coil domain. However, they also bind to
several other proteins (Kim et al., 1996; Urano et al.,
2002). In this study, we identiﬁed vimentin as a novel
binding partner of TRIM16 in neuroblastoma and lung
cancer cells. At the protein level, TRIM16 expression
correlates inversely with vimentin expression. Vimentin
is initially expressed in nearly all neuronal precursors
in vivo, and is replaced by neuroﬁlaments shortly after
the immature neurons become post-mitotic, and vimentin
is essential for neuritogenesis in culture (Yabe et al.,
2003). In breast cancer cells, the transition from
epithelial keratin to mesenchymal vimentin expression
marks an important step in the malignant progression of
breast cancer cells (Vora et al., 2009). Our data showed
that downregulation of vimentin was required for
TRIM16’s effects on cell motility, indicating that loss
of TRIM16 function or expression may increase the
invasiveness of neuroblastoma cells. Because over-
expression of TRIM16 did not change the vimentin
mRNA expression level, it is probable that TRIM16
regulated vimentin at the post-translational level. In the
scratch wound assay, overexpression of vimentin alone
did not affect wound ﬁlling due to the presence of
abundant endogenous vimentin in the cells. When both
proteins are co-expressed, overexpression of TRIM16
downregulates endogenous vimentin expression, and
therefore, overexpressed vimentin interferes with
TRIM16’s effect on cell mobility, but not with its effect
on cell proliferation.
Similar to PML and hemopoietic lineage switch 5,
which are members of the TRIM protein family (Mu
et al., 1997; Lalonde et al., 2004), TRIM16 was able to
reduce the growth of neuroblastoma cells, inhibit colony
formation and suppress tumour development, indicating
that TRIM16 is a tumour suppressor protein. Elevated
levels of TRIM16 can reduce cell growth, indicating that
TRIM16 might directly regulate the cell cycle machin-
ery. As a step towards understanding the role of
TRIM16 in cell cycle progression, E2F1 was identiﬁed
as a novel TRIM16 binding partner and its expression is
inversely correlated with TRIM16 expression in the
nucleus. The E2F family of transcription factors are
centrally important in mammalian cell division. E2Fs
are also targets of a variety of oncogenes and tumour
suppressor genes (Trimarchi et al., 2002). Therefore, it is
likely that the TRIM16 and E2F1 interactions are linked
to TRIM16’s tumour suppression function. Further-
more, the E2F transcription factor is best known for its
ability to regulate cell cycle progression by coordinating
a large group of genes involved in G1-to-S phase
transition. The hypophosphorylated retinoblastoma
protein (pRb) repressed E2F activity by shielding the
E2F transactivation domain, leading to restriction of
cell cycle progression (Weinberg, 1995). Our previous
data provided evidence that TRIM16 overexpression
correlated with inhibited cell growth through its effects
on cyclin D1 and phospho-Rb (Raif et al., 2009).
As deregulation of E2F transcriptional activity due to
alterations in the p16(INK4a)–cyclin D1–Rb pathway is
a hallmark of human cancer (Johnson et al., 2006), our
ﬁndings suggest that TRIM16 may have a critical role in
cell cycle progression, and that the effect of TRIM16 on
cell proliferation may be through translocation to the
nucleus, interaction with E2F1 and downregulation of
nuclear E2F1 in neuroblastoma cells.
The TRIM/RBCC proteins self-associate, mainly
through their coiled-coil region. Homo-interaction
results in the formation of large protein complexes,
which identify different discrete nuclear and/or cyto-
plasmic sub-cellular compartments (Reymond et al.,
2001). The presence of the RING domain and its strong
association with ubiquitination suggest a role for this
protein family in the ubiquitin-mediated proteolysis.
The RING ﬁnger domain has been found to have a
critical role in mediating the transfer of ubiquitin both
to heterologous substrates, as well as to the RING
proteins themselves. This domain is therefore a char-
acteristic signature of many E3 ubiquitin ligases
(Joazeiro and Weissman, 2000). TRIM16 is missing
the RING ﬁnger domain, but it has both B-box1 and
B-box2, which share a similar but distinct pattern of
cysteine and histidine residues (Borden et al., 1993).
Accumulating evidence suggests that B-boxes mediate
protein–protein interactions speciﬁc to each TRIM class
(Peng et al., 2000; Short et al., 2002; Mrosek et al.,
2008). It is unclear how overexpressed TRIM16 reduced
vimentin and E2F1 protein levels. It is possible that
TRIM16 acts as an E3 ubiquitin ligase, and targets these
proteins for proteolysis and promotes growth inhibition
in neuroblastoma cells.
TRIM16 is expressed in most normal and cancer cells,
but is mainly localized to the cytoplasmic component of
cancer cells. In this study we show that TRIM16 acts as
a tumour suppressor by its inhibitory effects on proteins
in both the nuclear and cytoplasmic compartments.
These data suggest that TRIM16 may have transactiva-
TRIM16 acts as a tumour suppressor in neuroblastoma cells
GM Marshall et al
6180
Oncogenetion-dependent effects and transactivation-independent
effects. In agreement with our observations are the
recent ﬁndings that p53 can act as a tumour suppressor
in both cytoplasmic and nuclear compartments of
cancer cells. In addition to being a nuclear transcription
factor regulating genes involved in apoptosis and cell
cycle, p53 has additional activities in the cytoplasm,
where it triggers apoptosis and inhibits autophagy
(Green et al., 2009).
As TRIM16 has been demonstrated to suppress
tumour growth, cell migration and sensitize cancer cells
to retinoids, our ﬁndings highlight TRIM16 as a
potential drug development target for the treatment of
cancers overexpressing vimentin and E2F1 proteins.
Agents that increase the cytoplasmic and/or nuclear
levels of TRIM16 might be expected to inhibit cell
migration and replication, respectively, and, moreover,
enhance the anticancer effects of differentiation thera-
pies, such as retinoids.
Materials and methods
Plasmid construction and stable transfection
The TRIM16 full-length cDNA was subcloned into the
pcDNA3.1( )/myc.His vector at the EcoRI multi-cloning site
(Cheung et al., 2006). The TRIM16-overexpressed BE(2)-C
stable cell lines were established with transfection of
pcDNA3.1( )/TRIM16/myc-His vector or the pcDNA/myc-
His empty vector. The two clones of overexpression of
TRIM16 (TRIM16-4 and TRIM16-5) and two empty vector
clones (EV-1 and EV-8) were selected for further studies.
The TRIM16-GFP deletion mutants were produced by
OriGene (Rockville, MD, USA). The deletion mutants
were synthesized by PCR of full-length TRIM16 cDNA
(NM_006470.3). The ﬁnal mutants were in the pCMV6-AC-
GFP vector. The mutant products correspond to the following
amino acid (AA) sequences; AA 1–564 (full-length), AA
161–564 (M1), AA 290–564 (M2) and AA 1–372 (M3).
Immunohistochemistry
Parafﬁn-embedded section of neuroblastoma patients’ tissue
was obtained from Paediatric Anatomical Pathology, South
Eastern Area Laboratory Services (SEALS). The slides were
incubated with rabbit anti-TRIM16 (Bethyl Laboratories,
Montgomery, TX, USA) at 1mg/ml or rabbit anti-class III
b-tubulin at 1 in 1000 dilution overnight at 41C. The secondary
antibody used was goat anti-rabbit immunoglobulin/biotiny-
lated (Dako, Glostrup, Denmark) at 1 in 500 dilutions for 1h
at room temperature. The biotinylated antibody was then
labelled with streptavidin-HRP (Dako) for 45min at room
temperature. The sections were developed with 3,30-diamino-
benzidine tetrahydrochloride (Dako) and counterstained with
haematoxylin.
Immunohistochemistry quantiﬁcation
Among the 21 neuroblastoma tumours, there were three in
stage I, six in stage II, four in stage III, seven in stage IV and
one in stage IVS, by the Evans staging system (Evans et al.,
1971). The positive staining of TRIM16 was analysed on
digitally captured images using the Aperio ScanScope XT slide
scanner (Aperio Technologies, Vista, CA, USA) (Brennan
et al., 2008; Rexhepaj et al., 2008). At least three of each
differentiated (X5% of neuroblasts toward ganglion cells) and
poorly differentiated regions (p5% of neuroblasts toward
ganglion cells) with an area of minimum 10000mm
2 were
selected and analysed using colocalization algorithms with
ImageScope (Aperio Technologies) (Joshi, 2000).
Tumourigenicity assays
Tumourigenicity was determined by injecting 5 10
6 of
TRIM16 or empty vector stably tranfected BE(2)-C cells
subcutaneously into 6–8-week-old female BALB/c nude mice.
Tumour volumes were measured twice a week using callipers,
and the tumour mass was determined after 4 weeks post
engraftment.
Transient transfection with plasmid DNA or siRNA
Cells (1 10
6) were transfected with either 15mg of TRIM16
expression vector or empty vector for 72h before harvesting
for transient transfection experiments. Cells were transfected
with either 20nM control siRNA (Dhamarcon, Lafayette, CO,
USA), or siRNA speciﬁc to TRIM16 (Ambion, Foster City,
CA, USA) or E2F1 (Dhamarcon) before harvesting for siRNA
gene knockdown experiments.
Confocal ﬂuorescence microscopy images
The BE(2)-C cells were ﬁxed in 10% formalin, and then non-
speciﬁc staining was blocked in 10% fetal calf serum/
phosphate-buffered saline. The cells were incubated in 5%
fetal calf serum/phosphate-buffered saline with goat anti-
vimentin antibody (1:400) and custom TRIM16 rabbit anti-
body (1:100). The cells were then incubated with Alexa Fluor
555 anti-goat IgG (1:1000) and Alexa Fluor 488 anti-rabbit
IgG (1:1000), the cells were then mounted in VectaShield with
40,6-diamidino-2-phenylindole. Images were collected with a
Zeiss LSM 510 META confocal ﬂuorescence microscope
(Zeiss, Jena, Germany) using a  63 oil Plan-apochromat
objective (NA, 1.4; Zeiss).
Scratch wound assays and migration assay
For scratch wound assays, BE(2)-C cells were transfected with
either 15mg of TRIM16 expression vector or empty vector with
Lipofectamine 2000. For the double transfection assays, 10mg
of TRIM16 expression vector and 10mg of vimentin expression
vector were transfected into the cells. After 48h from
transfection, cells were grown to 90–100% conﬂuence and
wounded using 20ml pipette tips, and the distance between the
wound was measured with Image J software (National Insti-
tutes of Health, Bethesda, MD, USA) at various time points.
For migration assay, BE(2)-C cells were serum starved
for 2h and then 4 10
4 cells were seed on Transwell inserts
pre-coated with collagen IV on the underside of the insert.
Transwell inserts were placed in companion plates containing
media with 10% fetal calf serum and the cells were allowed to
migrate at 371C. The migration index is the percentage of the
migrated cells divided by the total number of cells in the wells.
Immunoprecipitation assays and western blots
Lysates were immunoprecipitated with anti-TRIM16 (Bethyl
Laboratories) or anti-myc tag antibody (Cell Signalling
Technology, Danvers, MA, USA). Anti-vimentin antibody,
anti-E2F1 antibody and anti-Myc tag antibody were used in
immunoblots. Rabbit polyclonal actin antibody (Sigma, St
Louis, MO, USA), and Histone H3 antibody and anti-
GAPDH antibody were used to normalize for differences in
whole cell lysates, nuclear or cytoplasmic protein loading,
respectively.
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